CN106511976A - Composition for relieving gynecologic inflammation and improving immunity - Google Patents
Composition for relieving gynecologic inflammation and improving immunity Download PDFInfo
- Publication number
- CN106511976A CN106511976A CN201610937699.3A CN201610937699A CN106511976A CN 106511976 A CN106511976 A CN 106511976A CN 201610937699 A CN201610937699 A CN 201610937699A CN 106511976 A CN106511976 A CN 106511976A
- Authority
- CN
- China
- Prior art keywords
- parts
- lactobacillus
- cfu
- hundred million
- lactobacillus reuteri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 27
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 27
- 230000036039 immunity Effects 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 47
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 47
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 42
- 101100207366 Curvularia clavata TR02 gene Proteins 0.000 claims abstract description 24
- 101100207371 Curvularia clavata TR08 gene Proteins 0.000 claims abstract description 22
- 102000008186 Collagen Human genes 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 20
- 229920001202 Inulin Polymers 0.000 claims abstract description 20
- 235000020237 cranberry extract Nutrition 0.000 claims abstract description 20
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 20
- 229940029339 inulin Drugs 0.000 claims abstract description 20
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 19
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 19
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 18
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 18
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 18
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 17
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 18
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 14
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 14
- 241000186660 Lactobacillus Species 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 2
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 2
- 229920001436 collagen Polymers 0.000 abstract 1
- 230000001332 colony forming effect Effects 0.000 abstract 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000975 dye Substances 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000004043 dyeing Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 201000010927 Mucositis Diseases 0.000 description 7
- 230000003628 erosive effect Effects 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000010409 thin film Substances 0.000 description 6
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 5
- 239000000905 isomalt Substances 0.000 description 5
- 235000010439 isomalt Nutrition 0.000 description 5
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 241000756943 Codonopsis Species 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- -1 phosphoric acid hydrogen Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a composition for relieving gynecologic inflammation and improving immunity. The composition for relieving gynecologic inflammation and improving immunity comprises 2 to 8 parts of stachyose, 3 to 9 parts of inulin, 1 to 4 parts of cranberry extracts, 2 to 6 parts of isomaltooligosacharide, 0.5 to 2.5 parts of collagen, 3 to 4-billion CFU (Colony-Forming Unit) of lactobacillus plantarum, 3.5 to 4-billion CFU of lactobacillus reuteri TR02, 3.5 to 4.5-billion CFU of lactobacillus rhamnosus (L. rhamnosus) TR08, and 1 to 1.5-billion CFU of lactobacillus acidophilus. The invention further provides a preparation method and application of the composition. The composition is simple in preparation process, wide in raw material source, low in cost, convenient to use, capable of greatly improving human immunity, and effective in treating gynecologic inflammation.
Description
Technical field
The invention belongs to biological technical field, more particularly to a kind of compositionss for alleviating gynecological inflammation enhance immunity.
Background technology
Gynecological inflammation refers to the caused disease of female genital system infection, and gynecological inflammation is individual common in daily life
Disease is also intractable diseases, and especially in married woman, to send out rate high for disease, common symptom have menoxenia, dysmenorrhea, adnexitis,
Pelvic inflammatory disease, cervicitises, endometritis, vaginal discharge have abnormal flavour etc., and what is had even causes sterility and infertility.Gynecological inflammation
Prevalence is high, and high recurrence rate drastically influence the physical and mental health of women.
Various Lower Female Genital Tract diseases are lacked of proper care due to microecology in vaginas system balancing, such as bacterial vaginitiss,
Colpitis mycotica, trichomonal vaginitis etc..The at present measure for the treatment of vaginal infection is mainly with antibiotic, metronidazole, female
Preparation etc. of hormone and acidifying vagina is killing intravaginal pathogenic microorganism.But, above-mentioned therapy to a certain extent can
Suppress normal flora, cause the excessive multiplication of pathogenic bacterium or conditioned pathogen, so as to cause repeated infection or multiple infection, increase
Plus the difficulty and cost for the treatment of.Medicine use time is long will to produce drug resistance, have certain side effect to hepatic and renal function,
Larger is endangered to patient.And using Chinese medicine or Chinese patent drugs for treatment time long, therapeutic effect is not satisfactory.At present, reproductive tract are adjusted
Flora, it is if using probiotic bacteria, generally by interior use suppository, oral of less types, in-convenience in use.
The content of the invention
Technical problem：In order to solve the defect of prior art, the invention provides a kind of gynecological inflammation of alleviating improves immunity
The compositionss of power.
Technical scheme：A kind of compositionss of alleviation gynecological inflammation enhance immunity that the present invention is provided, including stachyose 2-8
Part, inulin 3-9 parts, Cranberry extract 1-4 part, oligomeric isomaltose 2-6 parts, collagen protein 0.5-2.5 parts, Lactobacillus plantarum
Hundred million CFU of 30-40, Lactobacillus reuteri (Lactobacillus reuteri) hundred million CFU of TR02 35-40, lactobacillus rhamnosuss
(L.rhamnosus) hundred million CFU of hundred million CFU of TR08 35-45, bacillus acidophilus 10-15.
Preferably, including stachyose 4-6 parts, inulin 5-7 parts, Cranberry extract 2-3 part, oligomeric isomaltose 3-5
Part, collagen protein 1-2 parts, hundred million CFU of Lactobacillus plantarum 33-37, Lactobacillus reuteri (Lactobacillus reuteri) TR02
Hundred million CFU of 37-39, lactobacillus rhamnosuss (L.rhamnosus) TR08 39-41 hundred million CFU, hundred million CFU of bacillus acidophilus 11-13.
As it is another kind of preferably, including 5 parts of stachyose, 6 parts of inulin, 2.5 parts of Cranberry extract, oligomeric isomaltose 4
Part, 1.5 parts of collagen protein, 3,500,000,000 CFU of Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus reuteri) TR02 38
Hundred million CFU, lactobacillus rhamnosuss (L.rhamnosus) TR08 4,000,000,000 CFU, 1,200,000,000 CFU of bacillus acidophilus.
Present invention also offers the preparation method of the compositionss of above-mentioned alleviation gynecological inflammation enhance immunity, including following step
Suddenly：
Stachyose, inulin, Cranberry extract, oligomeric isomaltose, collagen protein are weighed respectively, are mixed；Add plant
Thing lactobacilluss, Lactobacillus reuteri (Lactobacillus reuteri) TR02, lactobacillus rhamnosuss (L.rhamnosus)
TR08, bacillus acidophilus, mix, obtain final product.
Present invention also offers application of the above-mentioned composition in treatment gynecological inflammation medicine is prepared.
Present invention also offers application of the above-mentioned composition in enhance immunity medicine is prepared.
Beneficial effect：The compositionss preparation process is simple of present invention offer, raw material sources are extensive, with low cost, user
Just, body immunity is greatly improved, treatment gynecological inflammation effect is good.
Description of the drawings
Bacterium colony figures of the Fig. 1 for Lactobacillus reuteri (Lactobacillus reuteri) TR02.
Bacterium colony enlarged drawings of the Fig. 2 for Lactobacillus reuteri (Lactobacillus reuteri) TR02.
Bacterium colony figures of the Fig. 3 for lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08.
Bacterium colony enlarged drawings of the Fig. 4 for lactobacillus rhamnosuss (Lactobacillus rhamnosus) TR08.
Specific embodiment
In the present invention：
Stachyose is purchased from Shandong Xi Wang groups
Inulin is purchased from hundred Long Chuan gardens biotech inc of Shandong
Cranberry extract is purchased from hundred Long Chuan gardens biotech inc of Shandong
Oligomeric isomaltose is purchased from Shandong Xi Wang groups
Collagen protein is purchased from Shandong Xi Wang groups
Lactobacillus plantarum is purchased from hundred Long Chuan gardens biotech inc of Shandong
Bacillus acidophilus are purchased from hundred Long Chuan gardens biotech inc of Shandong
Lactobacillus reuteri (Lactobacillus reuteri) TR02, its Classification And Nomenclature are Lactobacillus reuteri
(Lactobacillus reuteri) TR02, in China typical culture collection center (abbreviation CCTCC) preservation, depositary institution
Address：Wuhan City, Hubei Province Wuchang District Wuhan University, postcode is 430072, and its deposit number is：CCTCC
No.2016546, preservation date are on October 10th, 2016.
The separation of bacterial strain
1st, strain and culture medium and condition of culture
(1) bacterium source
From certain military region health soldier's feces of China.
(2) culture medium
Plating medium：1000mL distilled water, peptone 10g, glucose 20g, yeast powder 9g, sodium acetate 5g, phosphoric acid hydrogen
Dipotassium 2g, Triammonium citrate 2g, cysteine 0.5g, magnesium sulfate 0.2g, manganese sulfate 0.05g, tween 1ml, agar powder 15-20g,
pH5.5-6.5。
2nd, the separation and identification of bacterial strain
(1) separation of bacterial strain
Proper amount of fresh feces are taken in glove box after sterilized process in advance and is placed in the aseptic examination for being loaded with aseptic culture medium
Guan Zhong, fully shaking are vortexed and mix；
The feces solution for mixing is vortexed as stock solution with above-mentioned fully shaking, ten times of gradient dilutions is done to suitable gradient, is taken 100
μ l are spread evenly across in MRS+0.05% cysteine solid plate culture medium, are subsequently taken out and are placed in anaerobic jar, 37 DEG C of anaerobism
Overnight incubation.
On next day visible flat board, length has the bacterium colony of form different sizes, special with reference to Lactobacillus reuteri colonies typical form
Levy, some representational bacterium colonies of picking make secondary line purification process, flat board anaerobism activates 1 day, obtains culture, subsequently do bacterium
Strain identification.
(2) identification of bacterial strain
Gram’s staining Morphological Identification：
A, smear：Sterilized microscope slide is taken in laboratory table, is marked with marking pen on slide, be easy to observation, with
Afterwards slide is inverted, and then 10 μ l physiological saline solution is drawn with pipettor and is uniformly coated at mark, is chosen with liquid-transfering gun then
Take pure culture to be uniformly dissolved in normal saline, coated face is unsuitable excessive.
B, drying：Specimen is faced upwards, the both sides of hand-held microscope slide one end, carefully on alcohol burner, eminence adds slightly
Heat, makes moisture evaporation, but be sure not it is long against flame or heat time heating time, in case specimen is baked withered and is deformed.
C, fixation：It is fixed usually to utilize high temperature, one end of hand-held microscope slide, specimen upwards, at the alcohol burner flame as early as possible
Back and forth through 2-3 time, altogether about 2-3 second kinds, and touch skin with the heating of the microscope slide back side frequently unconsciously are scalded to be advisable excessively and (are not surpassed
Cross 60 DEG C), place after cold, dyeed.
D, just dye：The Deca ammonium oxalate crystal violet 1-2 drops on smear thin film, make dyeing liquor cover smear, dye about 1min.
E, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
F, mordant dyeing：About 300ul iodine solutions are drawn with 100-1000ul liquid-transfering guns to drop on smear thin film, is covered dyeing liquor and is applied
Piece, dyes about 1min.
G, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
H, decolouring：Tilting microscope slide, 95% ethanol decolorization of Deca, not showing purple to the ethanol for flowing out, about take
20-30S, is washed immediately.
I, redye：The Deca husky of common dye dye liquor 1-2 drops on smear thin film, make dyeing liquor cover smear, dye about 1min.
J, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
K, drying, observation：Water droplet is sopped up with absorbent paper, treats that sample slice is done under rearmounted microscope, use low power sem observation, found
Immersion oil being dripped after purpose thing on slide, the form and color of antibacterial being observed with oil mirror, purple is gram positive bacteria, red
Color is gram negative bacteria.
As a result show：The bacterial strain is gram positive bacteria.
The measure of 16S rRNA sequences：
The PCR primers that use of amplification of 16S rRNA genes be general antibacterial primer 8F (5 '-
CACGGATCCAGAGTTTGAT (C/T) (A/C) TGGCTCAG-3 ') and 1510R (5 '-GTGAAGCTTAGGG (C/T)
TACCTTGTTACGACTT-3 ') product entrusts qualified third party's laboratory to carry out sanger sequencings.Using BLAST algorithm
Sequence and 16S rRNA genes are compared in GenBank data bases, adjacent tree is set up using 4.0 programs of MEGA.
BLAST analyses show that TR02 bacterium are sufficiently close to Lactobacillus reuteri (99% relationship (as shown in SEQ ID No.1)
Property).
Lactobacillus rhamnosuss (L.rhamnosus) TR08, its Classification And Nomenclature are lactobacillus rhamnosuss (Lactobacillus
Rhamnosus) TR08, in China typical culture collection center (abbreviation CCTCC) preservation, depositary institution address：Hubei Province is military
Han Shi Wuchang Districts Wuhan University, postcode is 430072, and its deposit number is：CCTCC NO.M2016548, preservation date is
On October 10th, 2016.
The separation of bacterial strain
1st, strain and culture medium and condition of culture
(1) bacterium source
From certain military region health soldier's feces of China
(2) culture medium
Plating medium：1000mL distilled water, peptone 10g, glucose 20g, yeast powder 9g, sodium acetate 5g, phosphoric acid hydrogen
Dipotassium 2g, Triammonium citrate 2g, cysteine 0.5g, magnesium sulfate 0.2g, manganese sulfate 0.05g, tween 1ml, agar powder 15-20g,
pH5.5-6.5。
2nd, the separation and identification of bacterial strain
(1) separation of bacterial strain
Proper amount of fresh feces are taken in glove box after sterilized process in advance and is placed in the aseptic examination for being loaded with aseptic culture medium
Guan Zhong, fully shaking are vortexed and mix；
The feces solution for mixing is vortexed as stock solution with above-mentioned fully shaking, ten times of gradient dilutions is done to suitable gradient, is taken 100
μ l are spread evenly across in MRS+0.05% cysteine solid plate culture medium, are subsequently taken out and are placed in anaerobic jar, 37 DEG C of anaerobism
Overnight incubation.
On next day visible flat board, length has the bacterium colony of form different sizes, with reference to lactobacilluss colonies typical morphological characteristic, picking
Some representational bacterium colonies make secondary line purification process, and flat board anaerobism activates 1 day, obtains culture, subsequently do identification of strains.
(2) identification of bacterial strain
Gram’s staining Morphological Identification：
A, smear：Sterilized microscope slide is taken in laboratory table, is marked with marking pen on slide, be easy to observation, with
Afterwards slide is inverted, and then 10 μ l physiological saline solution is drawn with pipettor and is uniformly coated at mark, is chosen with liquid-transfering gun then
Take pure culture to be uniformly dissolved in normal saline, coated face is unsuitable excessive.
B, drying：Specimen is faced upwards, the both sides of hand-held microscope slide one end, carefully on alcohol burner, eminence adds slightly
Heat, makes moisture evaporation, but be sure not it is long against flame or heat time heating time, in case specimen is baked withered and is deformed.
C, fixation：It is fixed usually to utilize high temperature, one end of hand-held microscope slide, specimen upwards, at the alcohol burner flame as early as possible
Back and forth through 2-3 time, altogether about 2-3 second kinds, and touch skin with the heating of the microscope slide back side frequently unconsciously are scalded to be advisable excessively and (are not surpassed
Cross 60 DEG C), place after cold, dyeed.
D, just dye：The Deca ammonium oxalate crystal violet 1-2 drops on smear thin film, make dyeing liquor cover smear, dye about 1min.
E, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
F, mordant dyeing：About 300ul iodine solutions are drawn with 100-1000ul liquid-transfering guns to drop on smear thin film, is covered dyeing liquor and is applied
Piece, dyes about 1min.
G, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
H, decolouring：Tilting microscope slide, 95% ethanol decolorization of Deca, not showing purple to the ethanol for flowing out, about take
20-30S, is washed immediately.
I, redye：The Deca husky of common dye dye liquor 1-2 drops on smear thin film, make dyeing liquor cover smear, dye about 1min.
J, washing：Tilting microscope slide, is rinsed with shallow bid current under water tap, until the water under washing in colourless is
Only.
K, drying, observation：Water droplet is sopped up with absorbent paper, treats that sample slice is done under rearmounted microscope, use low power sem observation, found
Immersion oil being dripped after purpose thing on slide, the form and color of antibacterial being observed with oil mirror, purple is gram positive bacteria, red
Color is gram negative bacteria.
As a result show：The bacterial strain is gram positive bacteria.
The measure of 16S rRNA sequences：
The PCR primers that use of amplification of 16S rRNA genes be general antibacterial primer 8F (5 '-
CACGGATCCAGAGTTTGAT (C/T) (A/C) TGGCTCAG-3 ') and 1510R (5 '-GTGAAGCTTAGGG (C/T)
TACCTTGTTACGACTT-3 ') product entrusts qualified third party's laboratory to carry out sanger sequencings.Using BLAST algorithm
Sequence and 16S rRNA genes are compared in GenBank data bases, adjacent tree is set up using 4.0 programs of MEGA.
BLAST analyses show that TR02 bacterium are sufficiently close to lactobacillus rhamnosuss (99% relationship (as shown in SEQ ID No.2)
Property).
Below the present invention is further illustrated.
Embodiment 1
The compositionss of alleviation gynecological inflammation enhance immunity, including 2 parts of stachyose, 9 parts of inulin, 1 part of Cranberry extract,
2 parts of oligomeric isomaltose, 0.5 part of collagen protein, 4,000,000,000 CFU of Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus
Reuteri) 3,500,000,000 CFU of TR02, lactobacillus rhamnosuss (L.rhamnosus) TR08 3,500,000,000 CFU, 1,000,000,000 CFU of bacillus acidophilus.
Its preparation method, comprises the following steps：Stachyose, inulin, Cranberry extract, oligomeric Isomalt are weighed respectively
Sugar, collagen protein, mix；Add Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus reuteri) TR02, Mus
Lee sugar lactobacilluss (L.rhamnosus) TR08, bacillus acidophilus, mix, obtain final product.
Embodiment 2
The compositionss of alleviation gynecological inflammation enhance immunity, including 8 parts of stachyose, 3 parts of inulin, 4 parts of Cranberry extract,
6 parts of oligomeric isomaltose, 2.5 parts of collagen protein, 3,000,000,000 CFU of Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus
Reuteri) hundred million CFU of TR0240, lactobacillus rhamnosuss (L.rhamnosus) TR08 4,500,000,000 CFU, 1,500,000,000 CFU of bacillus acidophilus.
Its preparation method, comprises the following steps：Stachyose, inulin, Cranberry extract, oligomeric Isomalt are weighed respectively
Sugar, collagen protein, mix；Add Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus reuteri) TR02, Mus
Lee sugar lactobacilluss (L.rhamnosus) TR08, bacillus acidophilus, mix, obtain final product.
Embodiment 3
The compositionss of alleviation gynecological inflammation enhance immunity, including 4 parts of stachyose, 7 parts of inulin, 3 parts of Cranberry extract,
3 parts of oligomeric isomaltose, 2 parts of collagen protein, 3,300,000,000 CFU of Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus
Reuteri) 3,900,000,000 CFU of TR02, lactobacillus rhamnosuss (L.rhamnosus) TR08 3,900,000,000 CFU, 1,100,000,000 CFU of bacillus acidophilus.
Its preparation method, comprises the following steps：Stachyose, inulin, Cranberry extract, oligomeric Isomalt are weighed respectively
Sugar, collagen protein, mix；Add Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus reuteri) TR02, Mus
Lee sugar lactobacilluss (L.rhamnosus) TR08, bacillus acidophilus, mix, obtain final product.
Embodiment 4
The compositionss of alleviation gynecological inflammation enhance immunity, including 6 parts of stachyose, 5 parts of inulin, 2 parts of Cranberry extract,
5 parts of oligomeric isomaltose, 1 part of collagen protein, 3,700,000,000 CFU of Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus
Reuteri) 3,700,000,000 CFU of TR02, lactobacillus rhamnosuss (L.rhamnosus) TR08 4,100,000,000 CFU, 1,300,000,000 CFU of bacillus acidophilus.
Its preparation method, comprises the following steps：Stachyose, inulin, Cranberry extract, oligomeric Isomalt are weighed respectively
Sugar, collagen protein, mix；Add Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus reuteri) TR02, Mus
Lee sugar lactobacilluss (L.rhamnosus) TR08, bacillus acidophilus, mix, obtain final product.
Embodiment 5
Alleviate the compositionss of gynecological inflammation enhance immunity, including 5 parts of stachyose, 6 parts of inulin, Cranberry extract 2.5
Part, 4 parts of oligomeric isomaltose, 1.5 parts of collagen protein, 3,500,000,000 CFU of Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus
Reuteri) 3,800,000,000 CFU of TR02, lactobacillus rhamnosuss (L.rhamnosus) TR08 4,000,000,000 CFU, 1,200,000,000 CFU of bacillus acidophilus.
Its preparation method, comprises the following steps：Stachyose, inulin, Cranberry extract, oligomeric Isomalt are weighed respectively
Sugar, collagen protein, mix；Add Lactobacillus plantarum, Lactobacillus reuteri (Lactobacillus reuteri) TR02, Mus
Lee sugar lactobacilluss (L.rhamnosus) TR08, bacillus acidophilus, mix, obtain final product.
The compositionss of embodiment 1 to 5 are used to treat gynecological inflammation：
Obtained gynecological inflammation treatment liquid in embodiment 1-5 is used for into clinical trial, each embodiment is treated：40 trouble
Person, wherein, 20 patients are cervical erosion severe patient, and 20 patients are vaginal mucosa inflammation severe patient；And each group is suffered from
Person by medical science be divided into slightly, moderate and severe, the patient numbers of every kind of degree are equal；Reference examples are treated with egg oil.
Above-mentioned composition is configured to into the medicinal liquid of concentration 5%, by medicinal liquid suction administrator, each 6-8ml, Huan Zheyang
Sleeping, medicinal liquid is injected genitals corresponding site by the high lift of both legs, quiet to lie 30-50 minutes.One course for the treatment of is five days；Same method
Using egg oil；3 courses for the treatment of are treated at most.
The effect for the treatment of is divided into four classes by medical science：Cure, it is effective, effective, invalid.The therapeutic effect for obtaining is as shown in table 1.
Table 1
| Group | Disease | Cure | It is effective | Effectively | It is invalid |
| Embodiment 1 | Cervical erosion | 20 | 0 | 0 | 0 |
| Vaginal mucosa inflammation | 19 | 1 | 0 | 0 | |
| Embodiment 2 | Cervical erosion | 19 | 1 | 0 | 0 |
| Vaginal mucosa inflammation | 20 | 0 | 0 | 0 | |
| Embodiment 3 | Cervical erosion | 20 | 0 | 0 | 0 |
| Vaginal mucosa inflammation | 20 | 0 | 0 | 0 | |
| Embodiment 4 | Cervical erosion | 20 | 0 | 0 | 0 |
| Vaginal mucosa inflammation | 18 | 2 | 0 | 0 | |
| Embodiment 5 | Cervical erosion | 20 | 0 | 0 | 0 |
| Vaginal mucosa inflammation | 19 | 1 | 0 | 0 | |
| Comparative example | Cervical erosion | 0 | 0 | 1 | 19 |
| Vaginal mucosa inflammation | 0 | 1 | 0 | 19 |
The compositionss of embodiment 1 to 5 are tested for enhance immunity
Above-mentioned composition is configured to into the medicinal liquid of concentration 5%, by 60 Kunming mouses (male and female half and half, 8 week old or so,
About 25-30g) stochastic averagina is divided into six groups (concrete group technology is shown in Table 2), using gastric infusion, after being administered 8 weeks, investigates each group
Impact to immune organ.Inspection target is spleen index and thymus index, and both increases contribute to the raising of immunity.
Table 2
| Matched group | 0.9% normal saline of same volume |
| Embodiment 1 | 4mg·kg-1·d-1 |
| Embodiment 2 | 4mg·kg-1·d-1 |
| Embodiment 3 | 4mg·kg-1·d-1 |
| Embodiment 4 | 2mg·kg-1·d-1 |
| Embodiment 5 | 6mg·kg-1·d-1 |
| Wild ginseng group | 4mg·kg-1·d-1 |
| Radix Codonopsis group | 4mg·kg-1·d-1 |
| Radix Astragali group | 4mg·kg-1·d-1 |
| Rhizoma Gastrodiae group | 4mg·kg-1·d-1 |
5 parts of wild ginseng (Radix Codonopsis, the Radix Astragali or Rhizoma Gastrodiae) is weighed respectively according to 2: 50: 50: 15 part by weight, is ground into 100-
The medicinal powder mixture of 200 mesh, is placed in container with cover with 100 part 50% of ethanol and is soaked 10 hours, be then refluxed for extraction 3
It is secondary, 3 hours every time.After 3 times reflux, extract, terminates, united extraction liquid, concentrating under reduced pressure obtain final product wild ginseng (Radix Codonopsis, the Radix Astragali or day
Fiber crops) group.
3 each group mice Different Organs index of table compares
Spleen index=spleen weight/body weight, thymus index=thymic weight/body weight
It can be seen from Table 3 that embodiment group and wild ginseng, Radix Codonopsis group, Radix Astragali group and Rhizoma Gastrodiae compare to have with matched group showing
The effect for increasing spleen index and thymus index of work.
SEQUENCE LISTING
<110>Its beneficial health science academy（Zhenjiang）Company limited
<120>A kind of compositionss for alleviating gynecological inflammation enhance immunity
<130> SC20161025001
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 1490
<212> DNA
<213> Lactobacillus reuteri
<220>
<221> misc_feature
<222> (1)..(1490)
<400> 1
gggtacgcgg cggtgtgcta tacatgcaag tcgtacgcac tggcccaact gattgatggt 60
gcttgcacct gattgacgat ggattaccag tgagtggcgg acgggtgagt aacacgtagg 120
taacctgccc cggagcgggg gataacattt ggaaacagat gctaataccg cataacaaca 180
aaagccacat ggcttttgtt tgaaagatgg ctttggctat cactctggga tggacctgcg 240
gtgcattagc tagttggtaa ggtaacggct taccaaggcg atgatgcata gccgagttga 300
gagactgatc ggccacaatg gaactgagac acggtccata ctcctacggg aggcagcagt 360
agggaatctt ccacaatggg cgcaagcctg atggagcaac accgcgtgag tgaagaaggg 420
tttcggctcg taaagctctg ttgttggaga agaacgtgcg tgagagtaac tgttcacgca 480
gtgacggtat ccaaccagaa agtcacggct aactacgtgc cagcagccgc ggtaatacgt 540
aggtggcaag cgttatccgg atttattggg cgtaaagcga gcgcaggcgg ttgcttaggt 600
ctgatgtgaa agccttcggc ttaaccgaag aagtgcatcg gaaaccgggc gacttgagtg 660
cagaagagga cagtggaact ccatgtgtag cggtggaatg cgtagatata tggaagaaca 720
ccagtggcga aggcggctgt ctggtctgca actgacgctg aggctcgaaa gcatgggtag 780
cgaacaggat tagataccct ggtagtccat gccgtaaacg atgagtgcta ggtgttggag 840
ggtttccgcc cttcagtgcc ggagctaacg cattaagcac tccgcctggg gagtacgacc 900
gcaaggttga aactcaaagg aattgacggg ggcccgcaca agcggtggag catgtggttt 960
aattcgaagc tacgcgaaga accttaccag gtcttgacat cttgcgctaa ccttagagat 1020
aaggcgttcc cttcggggac gcaatgacag gtggtgcatg gtcgtcgtca gctcgtgtcg 1080
tgagatgttg ggttaagtcc cgcaacgagc gcaacccttg ttactagttg ccagcattaa 1140
gttgggcact ctagtgagac tgccggtgac aaaccggagg aaggtgggga cgacgtcaga 1200
tcatcatgcc ccttatgacc tgggctacac acgtgctaca atggacggta caacgagtcg 1260
caagctcgcg agagtaagct aatctcttaa agccgttctc agttcggact gtaggctgca 1320
actcgcctac acgaagtcgg aatcgctagt aatcgcggat cagcatgccg cggtgaatac 1380
gttcccgggc cttgtacaca ccgcccgtca caccatggga gtttgtaacg cccaaagtcg 1440
gtggcctaac ctttatggag ggagccgcct aaggcggaca gagactgggt 1490
<210> 2
<211> 1474
<212> DNA
<213> Lactobacillus rhamnosus
<220>
<221> misc_feature
<222> (1)..(1474)
<400> 2
cgctggcggc gtgcctaata catgcaagtc gaacgagttc tgattattga aaggtgcttg 60
catcttgatt taattttgaa cgaatggcgg aagggtgaat aacccgtggg taacctggcc 120
ttaaatgggg gataaccttt ggaaaccgaa gctaataccg cataaatccc aaaaccgcat 180
ggttcttggc tgaaagatgg ggtaaactat cccttttgga tggacccccg gcgtattaac 240
ttgttggtga ggtaacggct ccaccaggga atgataccta acccaactga aaggttgatc 300
ggccaccttg ggactgagac ccggcccaaa ctcctaccgg agggagcaat agggaatctt 360
ccccaatgga cgccagtctg aaggaacaac cccccgtggg tgaaaaaggg tttccggtcc 420
taaaactctg ttgttggaaa aaaatggtcc gcaaaataac tggtggccgc gtggccgtat 480
ccaacccgaa agccacggct aactacctgc ccagcaccgc ggtaataccg aggtggcaag 540
cgttatccgg atttattggg cgtaaagcga gcgcaagcgg gttttttagt ctgatgggaa 600
agccctcggc ttaaccgaag aagtgcatcg gaaactggga aacttgaatg cagaagaaga 660
cagtggaact ccatgtgtag cggtgaaatg cctagatata tggaagaaca ccagtggcga 720
aagccgctgt ctggtctgta actgacgctg aagctccaaa gcctgggtag cgaacaggat 780
tagataccct gggagtccat gccgtaacga tgaatgctag tggtggaagg tttccgccct 840
tcaatgccga gcttacgcaa taagcaatcc gcctggggga atacgaccgg caggttgaaa 900
cttcaaagaa tttgaccggg gccgcacaag ccggtggagc attgtggttt aattcgaagc 960
acgcgaagaa cttaccaggt cttgacatct tttgatcact tgaagatcaa gtttcccttc 1020
gggcaaatga cagtggtgca tggttgtcgt cagctccgtg tcgtgagatg ttgggttaag 1080
tcccgcaacg agcgcaaccc ttatgactag ttgccagcat ttagttgggc actctagtaa 1140
gactgccggt gacaaaccgg aggaaggtgg ggatgacgtc aaatcatcat gccccttatg 1200
acctgggcta cacacgtgct acaatggatg gtacaacgag ttgcgagacc gcgaggtcaa 1260
gctaatctct taaagccatt ctcagttcgg actgtaggct gcaactcgcc tacacgaagt 1320
cggaatcgct agtaatcgcg gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac 1380
acaccgcccg tcacaccatg agagtttgta acacccgaag ccggtggcgt aaccctttta 1440
gggagcgagc cgtctaaggt ggacaaatga tact 1474
Claims (6)
1. it is a kind of alleviate gynecological inflammation enhance immunity compositionss, it is characterised in that：Including stachyose 2-8 parts, inulin 3-9
Part, Cranberry extract 1-4 part, oligomeric isomaltose 2-6 parts, collagen protein 0.5-2.5 parts, Lactobacillus plantarum 30-40 hundred million
CFU, Lactobacillus reuteri (Lactobacillus reuteri) hundred million CFU of TR02 35-40, lactobacillus rhamnosuss
(L.rhamnosus) hundred million CFU of hundred million CFU of TR08 35-45, bacillus acidophilus 10-15.
2. it is according to claim 1 it is a kind of alleviate gynecological inflammation enhance immunity compositionss, it is characterised in that：Including water
Threose 4-6 parts, inulin 5-7 parts, Cranberry extract 2-3 part, oligomeric isomaltose 3-5 parts, collagen protein 1-2 parts, plant breast
Hundred million CFU of bacillus 33-37, Lactobacillus reuteri (Lactobacillus reuteri) hundred million CFU of TR02 37-39, rhamnose breast bar
Hundred million CFU of bacterium (L.rhamnosus) TR08 39-41, hundred million CFU of bacillus acidophilus 11-13.
3. it is according to claim 1 it is a kind of alleviate gynecological inflammation enhance immunity compositionss, it is characterised in that：Including water
5 parts of threose, 6 parts of inulin, 2.5 parts of Cranberry extract, 4 parts of oligomeric isomaltose, 1.5 parts of collagen protein, Lactobacillus plantarum 35
Hundred million CFU, Lactobacillus reuteri (Lactobacillus reuteri) 3,800,000,000 CFU of TR02, lactobacillus rhamnosuss
(L.rhamnosus) 4,000,000,000 CFU of TR08,1,200,000,000 CFU of bacillus acidophilus.
4. it is a kind of alleviate gynecological inflammation enhance immunity compositionss preparation method, it is characterised in that：Comprise the following steps：Point
Another name water intaking threose, inulin, Cranberry extract, oligomeric isomaltose, collagen protein, mix；Add Lactobacillus plantarum, sieve
Yi Shi lactobacilluss (Lactobacillus reuteri) TR02, lactobacillus rhamnosuss (L.rhamnosus) TR08, acidophilus breast bar
Bacterium, mixes, obtains final product.
5. application of the compositionss described in any one of claims 1 to 3 in treatment gynecological inflammation medicine is prepared.
6. application of the compositionss described in any one of claims 1 to 3 in enhance immunity medicine is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610937699.3A CN106511976A (en) | 2016-10-25 | 2016-10-25 | Composition for relieving gynecologic inflammation and improving immunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610937699.3A CN106511976A (en) | 2016-10-25 | 2016-10-25 | Composition for relieving gynecologic inflammation and improving immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511976A true CN106511976A (en) | 2017-03-22 |
Family
ID=58293068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610937699.3A Pending CN106511976A (en) | 2016-10-25 | 2016-10-25 | Composition for relieving gynecologic inflammation and improving immunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511976A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107158041A (en) * | 2017-06-14 | 2017-09-15 | 镇江市天益生物科技有限公司 | A kind of probiotic composition for being used to treat gynaecological imflammation |
| CN107319563A (en) * | 2017-06-06 | 2017-11-07 | 上海真合生物技术有限公司 | Probiotic composition for strengthening anti-gynaecological imflammation ability |
| CN108157703A (en) * | 2018-02-01 | 2018-06-15 | 河北朗益生物科技有限公司 | A kind of Cranberry inulin probiotics solid beverage and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028288A (en) * | 2006-03-01 | 2007-09-05 | 大连森佰澳科技有限公司 | Membrane-strengthening agent |
| CN101411714A (en) * | 2007-10-15 | 2009-04-22 | 杜军 | Chemical substance for treating colpitis |
| CN103421715A (en) * | 2013-08-03 | 2013-12-04 | 青岛蔚蓝生物集团有限公司 | Lactobacillus rhamnosus and application thereof |
| CN104480032A (en) * | 2014-10-22 | 2015-04-01 | 天津科技大学 | Lactobacillus plantarum boosting immunological competence |
| CN105193860A (en) * | 2015-09-25 | 2015-12-30 | 南昌大学 | Method for application of artificially-cultured vaginal flora transplantation in treating gynecological inflammation |
-
2016
- 2016-10-25 CN CN201610937699.3A patent/CN106511976A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028288A (en) * | 2006-03-01 | 2007-09-05 | 大连森佰澳科技有限公司 | Membrane-strengthening agent |
| CN101411714A (en) * | 2007-10-15 | 2009-04-22 | 杜军 | Chemical substance for treating colpitis |
| CN103421715A (en) * | 2013-08-03 | 2013-12-04 | 青岛蔚蓝生物集团有限公司 | Lactobacillus rhamnosus and application thereof |
| CN104480032A (en) * | 2014-10-22 | 2015-04-01 | 天津科技大学 | Lactobacillus plantarum boosting immunological competence |
| CN105193860A (en) * | 2015-09-25 | 2015-12-30 | 南昌大学 | Method for application of artificially-cultured vaginal flora transplantation in treating gynecological inflammation |
Non-Patent Citations (1)
| Title |
|---|
| R.C.R. MARTINEZ等: "Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14" * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107319563A (en) * | 2017-06-06 | 2017-11-07 | 上海真合生物技术有限公司 | Probiotic composition for strengthening anti-gynaecological imflammation ability |
| CN107158041A (en) * | 2017-06-14 | 2017-09-15 | 镇江市天益生物科技有限公司 | A kind of probiotic composition for being used to treat gynaecological imflammation |
| CN108157703A (en) * | 2018-02-01 | 2018-06-15 | 河北朗益生物科技有限公司 | A kind of Cranberry inulin probiotics solid beverage and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI652343B (en) | Lactobacillus crimper (LACTOBACILLUS Crispatus) and application thereof | |
| CN104630083B (en) | A kind of Lactobacillus crispatus and its application in feminine care products | |
| EP3926040A1 (en) | Multi-lactobacillus composition and application thereof to vaginal health of females | |
| KR102215453B1 (en) | Bacteriophage therapy | |
| WO2017020784A1 (en) | Bacteroides fragilis and application thereof | |
| CN110982726B (en) | Lactobacillus crispatus and application thereof | |
| CN103409334B (en) | Inhibit the Bacillus acidi lactici and application thereof of vaginitis pathogen | |
| CN106511976A (en) | Composition for relieving gynecologic inflammation and improving immunity | |
| CN106957811B (en) | Format lactobacillus and Chinese medicine compound prescription with bacteriostasis and its application in treatment gynaecological imflammation | |
| CN112592871B (en) | Lactobacillus casei JYLC-374 and application thereof in product for improving male prostate | |
| CN106509913A (en) | Composition for regulating balance of intestinal flora | |
| CN113249255B (en) | Bacillus subtilis for preventing and controlling enteritis of poultry and application thereof | |
| CN110495522A (en) | A kind of feed Chinese medicine microecological preparation | |
| CN106520598A (en) | Lactobacillus rhamnosus and application | |
| CN106520599A (en) | Lactobacillus reuteri and applications | |
| CN114984114A (en) | Liquid fermentation traditional Chinese medicine microecological preparation and application thereof in aspect of resisting porcine epidemic diarrhea virus | |
| CN114561330B (en) | Composite microbial inoculum for preventing and treating genital tract infection | |
| CN114032190A (en) | Lactobacillus reuteri capable of fermenting dendrobium and effectively repairing solar dermatitis by fermentation liquor of dendrobium | |
| CN113274414A (en) | Probiotics preparation for repairing and maintaining vaginal microecological balance | |
| CN107586746B (en) | Lactic acid bacteria with effect of preventing and treating cow mastitis and application thereof | |
| CN116875480A (en) | Lactobacillus rhamnosus with antagonism to helicobacter pylori | |
| CN116218735A (en) | Bacteroides simplex strain and culture method and application thereof | |
| CN110938563B (en) | Lactobacillus BJ-REBORN001 and application thereof in preparation of helicobacter pylori inhibiting fermentation broth | |
| CN113975317A (en) | Application of coptis chinensis in preparation of product for promoting proliferation of beneficial bacteria in intestinal tract | |
| CN102337227B (en) | Lactobacillus plantarum and purpose thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
| RJ01 | Rejection of invention patent application after publication |